A ribosomal protein-rich tumor cell supernatant as a potent inducer of macrophage polarization for synergistic antitumor chemotherapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Cancer Research and Treatments · Immune cells in cancer · Autophagy in Disease and Therapy
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (63)
Show source-provided references
1. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer10.1186/s12943-024-01990-4 ↗
2. Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets10.1038/s41392-025-02124-y ↗
3. Decoding the spatiotemporal heterogeneity of tumor-associated macrophages10.1186/s12943-024-02064-1 ↗
4. Targeting macrophages: therapeutic approaches in cancer10.1038/nrd.2018.169 ↗
5. A timeline of tumour-associated macrophage biology10.1038/s41568-022-00547-1 ↗
6. Tumor associated macrophages and TAMs-Based anti-tumor nanomedicines10.1002/adhm.202100590 ↗
7. Macrophages at the interface of the co-evolving cancer ecosystem10.1016/j.cell.2023.02.020 ↗
8. Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization10.1016/j.ccell.2024.03.013 ↗
9. Interaction of tumor-associated macrophages and cancer chemotherapy10.1080/2162402X.2019.1596004 ↗
10. Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance10.1016/j.ccell.2022.08.012 ↗
11. Metabolic reprogramming of tumor-associated macrophages via adenosine-A2AR signaling drives cross-resistance in non-small cell lung cancer10.1016/j.drup.2025.101272 ↗
12. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance10.1038/s41698-024-00522-z ↗
13. M2 tumor-associated macrophage mediates the maintenance of stemness to promote cisplatin resistance by secreting TGF-β1 in esophageal squamous cell carcinoma10.1186/s12967-022-03863-0 ↗
14. Tumor-associated macrophages: an accomplice in solid tumor progression10.1186/s12929-019-0568-z ↗
15. The promising role of tumor-associated macrophages in the treatment of cancer10.1016/j.drup.2023.101041 ↗
16. Sphingolipid synthesis in tumor-associated macrophages confers immunotherapy resistance in hepatocellular carcinoma10.1126/sciadv.adv0558 ↗
17. DLL1-responsive PD-L1+ tumor-associated macrophages promote endocrine resistance in breast cancer10.1126/scitranslmed.adr6207 ↗
18. Responsive photosensitizer precursors reverse drug-induced secondary immunosuppression
19. Nanomaterials-Involved tumor-associated macrophages' reprogramming for Antitumor therapy10.1021/acsnano.3c12387 ↗
20. Reprogramming tumor-associated macrophages with a Se-Based core–satellite nanoassembly to enhance cancer immunotherapy10.1021/acs.nanolett.4c02657 ↗
21. Microbiota in cancer: current understandings and future perspectives10.1038/s41392-025-02335-3 ↗
22. Targeted reprogramming of tumor-associated macrophages for overcoming glioblastoma resistance to chemotherapy and immunotherapy10.1016/j.biomaterials.2024.122708 ↗
23. Cathepsin B-responsive programmed brain targeted delivery system for chemo-immunotherapy combination therapy of glioblastoma10.1021/acsnano.3c11958 ↗
24. Inhibiting chemotherapy immune tolerance and reversing tumor microenvironment by macrophage‐targeted Nanohybrid systems for enhancing tumor chemo‐immunotherapy10.1002/adfm.202501954 ↗
25. Drug-free immunotherapeutic biomimetic nanoparticles for treating triple-negative breast cancer10.1021/acsnano.5c18774 ↗
26. Metal-Phenolic outer membrane vesicles for cancer radioimmunotherapy10.1021/jacs.5c02774 ↗
27. Tumor lysates-constructed hydrogel to potentiate tumor immunotherapy10.1016/j.jconrel.2023.05.005 ↗
28. Personalized vaccination of tumor‐derived antigens and STING agonists for specific cancer immunotherapy10.1002/adma.202420325 ↗
29. Turning tumor cells into microvesicles as personalized cancer vaccines for cancer prevention and treatment10.1016/j.nantod.2024.102219 ↗
30. Engineered vesicular cancer vaccines for immunosuppressive microenvironment reversion and in situ vaccine generation10.1016/j.jconrel.2025.113658 ↗
31. Ex vivo photothermal treatment-induced immunogenic cell death for anticancer vaccine development10.1016/j.intimp.2023.111450 ↗
32. Introduction of an ultraviolet C-Irradiated 4T1 Murine breast cancer whole-cell vaccine model10.3390/vaccines11071254 ↗
33. Glioblastoma cell derived exosomes as a potent vaccine platform targeting primary brain cancers and brain metastases10.1021/acsnano.4c14573 ↗
34. Cold exposure therapy enhances single-atom nanozyme-mediated cancer vaccine therapy10.1021/acsami.4c20487 ↗
35. Boron neutron capture therapy‐derived extracellular vesicles via DNA accumulation boost antitumor dendritic cell vaccine efficacy10.1002/advs.202405158 ↗
36. Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination10.1016/j.biomaterials.2023.122218 ↗
37. Extracellular Matrix scaffold‐assisted tumor vaccines induce tumor regression and long‐term immune memory10.1002/adma.202309843 ↗
38. Cancer vaccines: discovery, development, and challenges for clinical translation10.1016/j.biomaterials.2025.123615 ↗
39. Engineering cellular vesicles for immunotherapy10.1021/accountsmr.4c00362 ↗
40. Nanovaccines with cell-derived components for cancer immunotherapy10.1016/j.addr.2021.114107 ↗
41. Emerging sonodynamic therapy‐based nanomedicines for cancer immunotherapy10.1002/advs.202204365 ↗
42. Designing nanotheranostics with machine learning10.1038/s41565-024-01753-8 ↗
43. Recent advances in tumor microenvironment hydrogen peroxide-responsive materials for cancer photodynamic therapy10.1007/s40820-019-0347-0 ↗
44. Nanoplatform-enhanced photodynamic therapy for the induction of immunogenic cell death10.1016/j.jconrel.2023.11.058 ↗
45. A novel hypocrellin B derivative for photodynamic therapy-driven cancer immunotherapy via triggering immunogenic cell death10.1016/j.nantod.2025.102809 ↗
46. In situ Hydrogel modulates cDC1‐Based antigen presentation and cancer stemness to enhance cancer vaccine efficiency10.1002/advs.202305832 ↗
47. DAMPs and DAMP-sensing receptors in inflammation and diseases10.1016/j.immuni.2024.03.002 ↗
48. Immunogenic nano-phthalocyanine enables oxygen-economic photodynamic therapy for hepatocellular carcinoma10.1016/j.engmed.2025.100103 ↗
49. Necroptosis-Mediated synergistic photodynamic and glutamine-metabolic therapy enabled by a biomimetic targeting nanosystem for cholangiocarcinoma10.1002/advs.202309203 ↗
50. Photodynamic therapy derived personalized whole cell tumor vaccine prevents postsurgery tumor recurrence and metastasis10.1002/smll.202308456 ↗
51. In situ sustained release hydrogel system delivering GLUT1 inhibitor and chemo-drug for cancer post-surgical treatment
52. Photoactivated nanovaccines10.1039/D5CS00608B ↗
53. DAMP sensing and sterile inflammation: intracellular, intercellular and inter-organ pathways10.1038/s41577-024-01027-3 ↗
54. A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells10.1080/2162402X.2018.1472187 ↗
55. Diversity and selectivity in mRNA translation on the endoplasmic reticulum10.1038/nrm3958 ↗
56. NIR-II photo-accelerated polymer nanoparticles boost tumor immunotherapy via PD-L1 silencing and immunogenic cell death
57. Intracellular localization and phototoxicity mechanisms of chlorin e6 derivatives and their liposomal formulations10.1134/S0006350919040250 ↗
58. A metal-phenolic network-assembled nanotrigger evokes lethal ferroptosis via self-supply loop-based cytotoxic reactions
59. Mitochondrion, lysosome, and endoplasmic reticulum: which is the best target for phototherapy?10.1016/j.jconrel.2022.09.037 ↗
60. Cell-surface photochemistry mediated calcium overload for synergistic tumor therapy10.1186/s12951-023-02090-z ↗
61. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine10.1186/s40425-019-0539-7 ↗
62. Hydrogel-Based growth factor delivery platforms: strategies and recent advances10.1002/adma.202210707 ↗
63. Harnessing Mn2+ ions and antitumor peptides: a robust hydrogel for enhanced tumor immunotherapy10.1021/jacs.4c14700 ↗